<DOC>
	<DOCNO>NCT00871156</DOCNO>
	<brief_summary>DDI study Tafenoquine Chloroquine</brief_summary>
	<brief_title>Tafenoquine/Chloroquine DDI Study</brief_title>
	<detailed_description>Safety , Tolerability , Pharmacokinetic Study Concomitant Chloroquine Tafenoquine Healthy Volunteers</detailed_description>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test ECGs . A subject clinical abnormality laboratory parameter outside reference range may include Investigator GSK medical monitor agree abnormality introduce additional risk factor interfere study procedure . Male female 18 55 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential childbearing potential negative urine pregnancy test screen Day 1 , agree use agree upon contraception method 56 day stop study drug . Body weight &gt; =60 kg ( 132 pound ) BMI within range 1932 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form A positive urine drug/alcohol screen screen Day 1 . History regular use tobacco nicotinecontaining product within 3 month prior screen . History illicit drug abuse within 6 month prior screen . History regular alcohol consumption within 6 month study Subjects unwilling comply lifestyle guideline require . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication . History sensitivity study medication component . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive urine hCG test screen prior dosing . Lactating female . Subject mentally legally incapacitate . A positive HIV antibody , Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . The subject 's systolic blood pressure outside range 90150mmHg diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100bpm male subject screen Day 1 . Cardiac conduction abnormality specify inprotocol Any significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject . History angina , ischemic heart disease , myocardial infarction , clinically significant arrhythmia . History epilepsy , convulsion psychological disorder . History porphyria . AST , ALT alkaline phosphatase &gt; 1.5 time upper limit normal and/or total bilirubin level outside normal range screening . A single repeat allow eligibility determination . Documented Glucose6phosphate dehydrogenase ( G6PD ) deficiency , determine quantitative assay enzyme activity . History hemoglobinopathy ; current past history methemoglobinemia methemoglobin percentage reference range screen . History previous eye surgery involve retina , Lasik surgery within 90 day , retinal/corneal abnormality . Any clinically significant abnormality screen Humphrey 102 visual field test . Best correct visual acuity bad 0.3 logMAR ( 20/40 Snellen equivalent ) ( i.e. , 20/40 good vision allow study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Drug-Drug Interaction</keyword>
</DOC>